Tuesday, 31 January 2012

Indian manufacturing pact for DSM

Mumbai, India-based Indoco Remedies will manufacture eight APIs for DSM's pharmaceutical products business unit. DSM said the alliance will leverage Indoco's product development and cGMP manufacturing capabilities and DSM's market access. Additionally DSM said the deal fits with its global expansion plans.
Hindu Business Line

Cambrex will begin supplying commercial quantities of sufentanil and sufentanil citrate in February


Pharmaceutics International has started construction of its 2,400m2 cGMP aseptic fill/finish manufacturing facility in Hunt Valley, MD


Ampac Fine Chemicals Rancho Cordova, CA, facility has been granted registration to manufacture Schedule II controlled substances

Pharmaceutical Business Review

Wednesday, 25 January 2012

Lonza results miss estimates, fires CEO

Lonza has reported its full year 2011 revenues before the Arch acquisition of CHF2.5m, up 5% in constant exchange rates, missing analyst estimates. The company also announced that its CEO, Stefan Borgas, would be leaving the company with immediate effect. Lonza's share price fell 13% on the day the results were announced. Lonza said its custom manufacturing continued to benefit from demand for outsourcing from pharmaceutical and biotech companies. The company said its capacity utilisation rate for small molecules was 78% and for biological molecules was 87% excluding the recently opened Singapore facility and it had increased the number of contracts it had signed.
Outsourcing Pharma

Strong year for Albemarle

Albemare reported a strong Q4 and full year 2011 for its fine chemistry business unit. Sales in Q4 rose 36% to $209m and income 62% to $43m. For the full year the unit reported record sales of$750m up 32% and income doubles to $140m. The company said that the unit is set for another strong year in 2012.
Seeking Alpha

Thursday, 19 January 2012

Dishman is planning to sell its Chinese API manufacturing facility in Shanghai

Wall Street Journal

Avecia Biotechnology plans acquisition

Avecia Biotechnology has identified a possible acquisition target that would expand its capabilities. Company President Detlef Rethage said it has chosen a company in the fill and finish business. Avecia has not indicated when the acquisition would be completed.
Mass High Tech

AMRI UK site receives GMP certificate

AMRI’s Holywell, UK, manufacturing facility has received a GMP certificate following an inspection in October 2011. The site also passes a US FDA audit in June 2011. AMRI said the former Excelsyn facility can now produce registered intermediates and active ingredients for use in humans and expands the range of projects that it can now conduct at this facility.

Tuesday, 17 January 2012

Scil Proteins will manufacture Actavis's recombinant protein, Reteplase

Pharmaceutical Business Review

Almac will manufacture MGB Biopharma's gram positive antibacterial compound, MGB-BP3

Manufacturing Chemist

Molecular Profiles to expand cGMP capacity

Molecular Profiles is adding a new £9m manufacturing facility at its Nottingham, UK, site. The new facility, which is due to open later this year, will add 3000m2 of space and provide six new GMP suites, new laboratories and a clinical packing suite. It is designed to enable flexibility of use and the manufacture of highly potent compounds up to OEB 4 level.

Carbogen Amcis acquires Creapharm

Dishman Pharmaceuticals subsidiary Carbogen Amcis has acquired Creapharm Parenterals for an undisclosed sum. The business, which will be renamed Carbogen Amcis SAS, adds complimentary formulation and lyophilisation services as well as sterile GMP-standard capabilities for the rapid supply of medicines, including highly potent compounds for preclinical and clinical trials to Carbogen Amcis.
Pharma Times

Tuesday, 10 January 2012

Pfenex will develop production strains and fermentation process conditions and supply bulk protein to ProZyme for use in research and diagnostics


Future of AMRI's Hungary facility in doubt

AMRI is considering options for its custom research and manufacturing facility in Budapest, Hungary. The company said the site had been losing money over the last two years and the company is considering transferring the activities to other sites.
Outsourcing Pharma

Angel Biotechnology's revenue for the year ended 31 December 2011 was £3.06m